Chongqing Primary Aldosteronism Study

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

1500 participants

Study Classification

OBSERVATIONAL

Study Start Date

2016-10-01

Study Completion Date

2028-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

We intends to conduct a series of original clinical research about PA, and establish a large cohort of PA and essential hypertension patients with long-term follow-up of cardiovascular events, renal end points etc. We will establish a large sample of blood, urine, adrenal tissue of the subjects, and the genomics,metabonomics, proteomics database, to explore the mechanism of the PA and target organ damage, risk factors, diagnostic methods and biomarkers.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Effect of Anti-hypertensive Medications on the Diagnostic Accuracy in Primary Aldosteronism

NCT04991961

Hypertension Primary Aldosteronism

COMPLETED

Prevalence of Primary Aldosteronism in Patients With Resistant Hypertension in China

NCT01459042

Hypertension, Resistant to Conventional Therapy

COMPLETED

Primary Aldosteronism: Prospective Screening Registry in China

NCT04020783

Primary Aldosteronism

RECRUITING

Primary Aldosteronism In Hypertensive Patients in China

NCT03155139

Hyperaldosteronism; Primary Hypertension Secondary

COMPLETED

Prospective Study on Primary Aldosteronism in Resistant Hypertension

NCT04213963

Resistant Hypertension Primary Aldosteronism Refractory Hypertension +3 more

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study will include the subjects of a series of studies on hypertension conducted by our team, including essential hypertension, PA subjects, and establish a large sample database and specimen bank through follow-up and omics analysis.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Primary Aldosteronism

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Primary aldosteronism

screened, confirmed and subtyped according to the guidelines.

no intervention

Intervention Type OTHER

no intervention

Essential hypertension

screened for PA and excluded the diagnosis of PA as well as other secondary hypertesion

no intervention

Intervention Type OTHER

no intervention

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

no intervention

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. hypertensive patients who completed ARR screening and necessary further tests;
2. Voluntary to sign the informed consent.

Exclusion Criteria

1. patients with severe cardiac, hepatic or renal dysfunction;
2. suspicious or confirmed other types of secondary hypertension, including Cushing's syndrome, pheochromocytoma and renal artery stenosis et al.

Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No